Evidence map›Paper›PMID 34016734›Full record

SynthesisNeurology(R) neuroimmunology & neuroinflammation2021

COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review.

Mahdi Barzegar, Omid Mirmosayyeb, Mahsa Gajarzadeh, Alireza Afshari-Safavi, Nasim Nehzat, Saeed Vaheb, Vahid Shaygannejad, Amir-Hadi Maghzi

Erratum issuedOpen access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Neurology(R) neuroimmunology & neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 59 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 3 pooled it
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 3 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Multiple sclerosis and COVID-19: a northern China survey.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  13. Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Mahdi BarzegarFrom the Department of Neurology (M.B., O.M., N.N., S.V., V.S.), School of Medicine, Isfahan University of Medical Sciences; Universal Council of Epidemiology (UCE) (M.G.), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences; Department of Biostatistics and Epidemiology (A.A.-S.), Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-6578-0250
Omid MirmosayyebFrom the Department of Neurology (M.B., O.M., N.N., S.V., V.S.), School of Medicine, Isfahan University of Medical Sciences; Universal Council of Epidemiology (UCE) (M.G.), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences; Department of Biostatistics and Epidemiology (A.A.-S.), Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Mahsa GajarzadehFrom the Department of Neurology (M.B., O.M., N.N., S.V., V.S.), School of Medicine, Isfahan University of Medical Sciences; Universal Council of Epidemiology (UCE) (M.G.), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences; Department of Biostatistics and Epidemiology (A.A.-S.), Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Alireza Afshari-SafaviFrom the Department of Neurology (M.B., O.M., N.N., S.V., V.S.), School of Medicine, Isfahan University of Medical Sciences; Universal Council of Epidemiology (UCE) (M.G.), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences; Department of Biostatistics and Epidemiology (A.A.-S.), Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Nasim NehzatFrom the Department of Neurology (M.B., O.M., N.N., S.V., V.S.), School of Medicine, Isfahan University of Medical Sciences; Universal Council of Epidemiology (UCE) (M.G.), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences; Department of Biostatistics and Epidemiology (A.A.-S.), Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Saeed VahebFrom the Department of Neurology (M.B., O.M., N.N., S.V., V.S.), School of Medicine, Isfahan University of Medical Sciences; Universal Council of Epidemiology (UCE) (M.G.), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences; Department of Biostatistics and Epidemiology (A.A.-S.), Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Vahid ShaygannejadFrom the Department of Neurology (M.B., O.M., N.N., S.V., V.S.), School of Medicine, Isfahan University of Medical Sciences; Universal Council of Epidemiology (UCE) (M.G.), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences; Department of Biostatistics and Epidemiology (A.A.-S.), Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. v.shaygannejad@gmail.com.ORCID 0000-0002-6226-0161
Amir-Hadi MaghziFrom the Department of Neurology (M.B., O.M., N.N., S.V., V.S.), School of Medicine, Isfahan University of Medical Sciences; Universal Council of Epidemiology (UCE) (M.G.), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences; Department of Biostatistics and Epidemiology (A.A.-S.), Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Brigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe systematically reviewed the literature on COVID-19 in patients with multiple sclerosis (MS).

methodsWe searched PubMed, Scopus, EMBASE, CINAHL, Web of Science, Google Scholar, and World Health Organization database from December 1, 2019, to December 18, 2020. Three conference abstract databases were also searched. We included any types of studies that reported characteristics of patients with MS with COVID-19.

resultsFrom an initial 2,679 publications and 3,138 conference abstracts, 87 studies (67 published articles and 20 abstracts) consisting of 4,310 patients with suspected/confirmed COVID-19 with MS met the inclusion criteria. The female/male ratio was 2.53:1, the mean (SD) age was 44.91 (4.31) years, the mean disease duration was 12.46 (2.27), the mean Expanded Disability Status Scale score was 2.54 (0.81), the relapsing/progressive ratio was 4.75:1, and 32.9% of patients had at least 1 comorbidity. The most common symptoms were fever (68.8%), followed by cough (63.9%), fatigue/asthenia (51.2%), and shortness of breath (39.5%). In total, 837 of 4,043 patients with MS with suspected/confirmed COVID-19 (20.7%) required hospitalization, and 130 of 4,310 (3.0%) died of COVID-19. Among suspected/confirmed patients, the highest hospitalization and mortality rates were in patients with no disease-modifying therapies (42.9% and 8.4%), followed by B cell-depleting agents (29.2% and 2.5%).

conclusionOur study suggested that MS did not significantly increase the mortality rate from COVID-19. These data should be interpreted with caution as patients with MS are more likely female and younger compared with the general population where age and male sex seem to be risk factors for worse disease outcome.

Indexed as

AdultCOVID-19FemaleHumansMaleMiddle AgedMultiple SclerosisSARS-CoV-2

Identifiers

PMID34016734
PMCPMC8142838
OpenAlexW3162833512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.